Ed Sheidlower is avoiding financials. But the Bryce Capital Management portfolio manager sees other sectors -- and stocks -- as good investments.   Read More

A few weeks ago I blogged about a couple analysts cautioning investors that shares of Irish drugmaker Elan would be volatile surrounding the Alzheimer's conference the end of this month.That has certainly proven to be the case, especially today as the second firm this week initiates coverage of the stock, but this time with a "Sell" rating.   Read More

Some traders are also turning bullish. John Mendelson of the Stanford Group issued a buy signal late in the day; traders tell me it was his 3rd buy signal in 5 years, and the prior two calls were very good.   Read More

At the risk of being ganged up on by the "Elanians" who will take umbrage with the fact that the biopharma team at Cowen and Company is not initiating coverage of the Irish drugmaker with a "screaming buy," I am blogging about the analysts' 50-page call on the stock today.    Read More

Ahead of the long holiday weekend I thought this would be as good a time as any to once again go through the "Pharma's Market" mailbag. A couple of blog readers complained about my "short" story about Amgen.   Read More

What are the best plays when the market enters bear territory?   Read More

As much as I tried to disconnect during my vacation last week, I couldn't escape the ubiquitous presence of pharmaceuticals in our everyday lives...   Read More

Following are the week’s biggest winners and losers. Find out why shares of Goldman Sachs and Wyeth popped while Coca-Cola and Denny’s dropped.   Read More

The stock market ends the week in negative territory with all major indexes down almost 2% or greater, led by the Dow which dropped almost 4% for the week and broke the 12,000 level for the first time since March.   Read More

On Tuesday we received word of three exciting medical advancements. Find out what’s happening and how to trade them.   Read More